di Reumatologia, Società Italiana, trans. 2026. “PO:07:108 | Achievement of Treatment Targets and Maintenance of Response With Upadacitinib in Patients With Moderate-to-Severe Rheumatoid Arthritis in a Real-World Setting: Final 2-Year Outcomes from the UPHOLD Study: Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service De Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento De Medicina, Facultad De Medicina, Universidad De La República, Montevideo, Montevideo, Uruguay; 7Unidad De Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia”. Reumatismo 77 (s1). https://doi.org/10.4081/reumatismo.2025.2306.